Using whole exome sequencing, Miao et al. showed a correlation between patients with metastatic ccRCC harboring PBRM1 loss-of-function mutations and improved outcomes following treatments with nivolumab (Miao et al., 2018). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.